CytomX inks $35M upfront deal with Moderna for mRNA-Probody therapies; milestones up to $1.2B

CytomX Therapeutics, Inc.

Upfront payment of $35M includes $5M pre-paid research funding; potential milestones total $1.2B.
Tiered royalties on net sales from high single digit to low-teen percentages per licensed product.
Moderna gets exclusive worldwide license to CytomX Probody platform for mRNA-encoded conditionally-activated therapies.
Moderna has a one-time option to participate in a future CytomX equity financing.
Collaboration covers oncology and non-oncology programs; Moderna can terminate on product-by-product basis after 2 years.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CytomX Therapeutics, Inc. entered into Collaboration and License Agreement with ModernaTX, Inc., a wholly-owned subsidiary of Moderna, Inc. valued at $35 million (effective 2022-12-30).

Action: entry
Agreement: collaboration
Counterparty: ModernaTX, Inc., a wholly-owned subsidiary of Moderna, Inc.
Value: $35 million
Effective: 2022-12-30

Exact text from the filing

On December 30, 2022, CytomX Therapeutics, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration and License Agreement”) with ModernaTX, Inc., a wholly-owned subsidiary of Moderna, Inc. (“Moderna”),

View on SEC.gov

Browse all material agreements →

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-002398

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.